



For release at 5:00 PM ET on May 29, 2007

Contact:

Christopher Thurman, +1 (404) 601-1430, ext. 1419

RFS Pharma Awarded NIH Grant to Develop Resistance Repellent Anti-HIV Drugs

Atlanta, GA, May 29, 2007 -- RFS Pharma, LLC, a clinical stage biotechnology company engaged in the discovery, development and commercialization of drugs for the treatment of viral infectious diseases, today announced the receipt of an R01 grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The principal goal of this \$400,000 grant is to develop novel nucleoside reverse transcriptase inhibitors (NRTI) that have excellent efficacy and safety profiles with resistance repellent properties.

“Our innovative nucleoside expertise, coupled with a comprehensive discovery program, has produced novel antiviral agents against HIV,” said Dr. Steven J. Coats, Senior Director of Chemistry and Principal Investigator of the grant for the company. “This is our company’s first NIH grant, and we are honored, that in this competitive environment, we were awarded such a prestigious four-year R01 grant.”

Nucleoside analogs interfere with the building blocks necessary for HIV replication machinery. NRTI are integral components of therapy for HIV-1 and other viral infections. The eight approved NRTI have limitations that include selection of drug-resistant HIV-1 variants that are cross-resistant with other NRTI.

About RFS Pharma, LLC

RFS Pharma, LLC, was founded in September 2004 and is located in a 26,500 sq. ft. state-of-the-art research facility in Tucker, Georgia. RFS Pharma is a privately owned biotechnology company with expertise in nucleoside chemistry, committed to the development of drugs to combat infections caused by drug-resistant HIV and hepatitis viruses. RFS Pharma’s lead product candidate is Amdoxovir (DAPD, AMDX), which is in advanced Phase 2 clinical studies for the treatment of HIV-1 infections. For further information about RFS Pharma, please refer to <http://www.rfspharma.com>.

Forward-looking Statements

“Safe Harbor” Statement: Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the US Private Securities Litigation Reform Act of 1995. Since this information may involve risks and uncertainties and be subject to change at any time, the Company's actual results may differ materially from expected results. The Company disclaims any obligation to update the statements contained in this Company press release.

SOURCE: RFS Pharma, LLC

#####